InvestorWire NewsRoom

Article

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Application Amid ‘New Era’ of Psychedelic Medicine
October 20, 2021

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Application Amid ‘New Era’ of Psychedelic Medicine

  • Substances such as psilocybin, ketamine and LSD are edging into mainstream culture, setting the stage for a paradigm shift in modern medicine
  • Cybin has filed an international patent application covering methods for the delivery of psychedelic medications by inhalation
  • The company is pursuing the effectiveness of using inhalation as a delivery method for psychedelic medications

Earlier this month, a Time magazine article reported on the “new era” of psychedelic medicine (https://ibn.fm/bfC3u). On the leading edge of this collective breakthrough is Cybin (NEO: CYBN) (NYSE American: CYBN), a company focused on progressing psychedelic therapeutics, addressing the mental health crisis and transforming the treatment landscape. As part of its mission, the company has filed an international patent application related to delivery methods of psychedelic medications (https://ibn.fm/vaIVQ). 

“As a growing number of states and cities move to decriminalize drugs, and investors flock to an emerging market for psychedelic health care, substances like psilocybin, ketamine and LSD are edging into mainstream culture—and setting the stage for a paradigm shift in modern medicine,” stated the Time article.  “Within the next few years, we could see psychedelic therapies prescribed for refractory depression and post-traumatic stress disorder (‘PTSD’), or used in palliative care among those facing a life-limiting illness. . . . It’s no coincidence that psychedelics are entering the conversation at the moment we most sorely need new ideas in mental health care.”

Committed to finding answers to the growing need for effective mental health care solutions, Cybin has filed an international patent application covering methods for the delivery of psychedelic medications by inhalation as well as devices for performing those methods.

The application, which is governed by the Patent Cooperation Treaty (“PCT”), would give Cybin potential to obtain patent coverage in 153 countries.

“The continued progression of our research programs guides our discovery of new molecules and differentiating treatment approaches,” said Cybin CEO Doug Drysdale. “Continued innovation, as demonstrated by our expanding IP portfolio, positions Cybin as a leading innovator in the development of putative psychedelic treatments for a variety of mental health conditions.”

Based on its research and study, Cybin is pursuing the effectiveness of using inhalation as a delivery method for psychedelic medications. Traditional oral drug administration presents certain challenges that CYBN believes can be alleviated through inhalation of the psychedelic substance. Specifically, the company reports, it expects inhalation delivery to facilitate optimized psychedelic session timing compared to oral administration of the same compounds, lower doses of psychedelic therapeutics while preserving efficacy, and providing health care providers with more control during psychedelic sessions.

The patent was filed in support of Cybin’s CYB004 preclinical development program. The patent would increase the company’s library of drug-delivery modalities focused on optimal delivery of psychedelics and strengthen Cybin’s growing IP portfolio. The filing also includes support for future research programs the company may undertake, including those exploring various ways to reduce or minimize negative side effects in psychedelic psychotherapy patients. The company may also look at ways to lower medication doses without impacting treatment efficacy while increasing the long-term efficacy of psychedelic sessions.

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).